SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-001556
Filing Date
2024-01-05
Accepted
2024-01-05 06:07:26
Documents
14
Period of Report
2024-01-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm242154d1_8k.htm   iXBRL 8-K 24414
2 EXHIBIT 99.1 tm242154d1_ex99-1.htm EX-99.1 40859
6 GRAPHIC tm242154d1_ex99-1img01.jpg GRAPHIC 3085
  Complete submission text file 0001104659-24-001556.txt   250998

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tbph-20240105_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tbph-20240105_pre.xml EX-101.PRE 22363
5 XBRL TAXONOMY EXTENSION SCHEMA tbph-20240105.xsd EX-101.SCH 3021
8 EXTRACTED XBRL INSTANCE DOCUMENT tm242154d1_8k_htm.xml XML 3331
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 24514382
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)